This leads to a decrease in the recruitment of tumor-associated neutrophils and an improvement in the immune microenvironment for anti-PD-1 immunotherapy, thereby enhancing the immunotherapeutic effect (82). The gene discussed is PDCD1; the disease is neoplasm.